ASCO GU 2021 Prostate Cancer

Viewing 1-20 of 83 articles

ASCO GU 2021: CTC Counts as a Biomarker of Prognosis and Response in Metastatic Castration-Resistant Prostate Cancer (mCRPC) from the CARD Trial

ASCO GU 2021: Back to Basics in Personalization: Returning to PTEN

ASCO GU 2021: 177Lu-PSMA-617 (LuPSMA) Versus Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer Progressing After Docetaxel: Updated Results Including Progression-Free Survival and Patient-Reported Outcomes (TheraP ANZUP 1603)

ASCO GU 2021: Biomarker Analysis from a Randomized Phase II Study of Olaparib with or Without Cediranib in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

ASCO GU 2021: Final Results from ACIS, a Randomized, Placebo-Controlled Double-Blind Phase 3 Study of Apalutamide and Abiraterone Acetate plus Prednisone (AAP) Versus AAP in Patients with Chemo-Naive Metastatic Castration-Resistant Prostate Cancer

ASCO GU 2021: Molecular Determinants Associated with Long-Term Response to Apalutamide in nmCRPC and Final Results from the ACIS Phase 3 Study - Discussion

ASCO GU 2021: Molecular Determinants Associated with Long-Term Response to Apalutamide in Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC)

ASCO GU 2021: The Role of PARP Inhibitors in Prostate Cancer: Is It a Sea Change or Just Another Incremental Change?

ASCO GU 2021: A Multicenter Retrospective Analysis Examining The Effect Of Dipeptidyl Protease 4 Inhibitors On Progression-Free Survival In Patients With Prostate Cancer

ASCO GU 2021: Concordance of BRCA1 and BRCA2, and ATM Mutations Identified in Matched Tumor Tissue and ctDNA in Men mCRPC Screened in the PROfound Study

ASCO GU 2021: The Efficacy and Safety of Nivolumab Plus Docetaxel For Chemotherapy-Naïve mCRPC in the Final Analysis of the CheckMate 9KD Arm B Trial

ASCO GU 2021: Progress and Promise in Treatment Personalization for Advanced Prostate Cancer - Lighting the Way: Lutetium in the Treatment Paradigm

ASCO GU 2021: An Exploratory Gene-by-Gene Analysis of Patients with mCRPC Treated with Olaparib in the PROfound Trial

ASCO GU 2021: A Phase III Study of Apalutamide vs Placebo In Patients with mCSPC Receiving ADT: Final Analysis Results From TITAN

ASCO GU 2021: Genomic Landscape of Advanced Prostate Cancer in Racial Minority Populations

ASCO GU 2021: PROSPER Subgroup Analysis by Age and Region: Overall Survival and Safety in Men With Nonmetastatic Castration-Resistant Prostate Cancer Receiving Androgen Deprivation Therapy Plus Enzalutamide

ASCO GU 2021: Overall Survival and Metastasis-Free Survival by Depth of PSA Decline in the Phase III PROSPER Trial of Men With nmCRPC Treated with Enzalutamide

ASCO GU 2021: Real-World Clinical Outcomes Study of Sequential Novel Antihormonal Therapy (NAH) or Ra-223 Treatment of mCRPC That Progressed After First-Line NAH

ASCO GU 2021: The Potential Role of Frailty in Modifying Quality-of-Life Related Outcomes in Metastatic Castration-Resistant Prostate Cancer Patients Receiving Docetaxel, Abiraterone, Enzalutamide, and Radium 223

ASCO GU 2021: Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-Resistant Prostate Cancer

1
2
3
4
5